2021. RFLSP.Russian.Finnish.Life.Science.Industry.EN

More documents

Recommendations

Info

§ training system in the field of modern chemical and biotechnological synthesis andthe interdisciplinary nature of modern technological platforms;§ demand for the results of the introduction of new drugs and production technologies:the lack of guaranteed incentives from the state for the development andcommercialization of new drugs and new types of pharmaceutical products against thethe common idea about better quality and consumer properties of imported products,which has a significant impact on the behavior of the patient and medical community;§ shortcomings of the state support measures system and insufficient efficiency ofpublic investments.34RUSSIAN-FINNISH LIFE SCIENCE INDUSTRYResearch and export directory
1.2.3 Forecasts for the development of the Russian pharmaceuticalmarketAccording to DSM Group forecasts, in 2021 the market capacity will reach 2,171 billion rubles.(+ 6% by 2020). Additional growth factors are not expected, the industry is waiting for therecovery of the pre-pandemic consumption structure.Dynamics of the Russian pharmaceutical market capacity, RUB bln(+4.7%) (+3.7%)1 523401226(+9.5%)(+7.7%) (+2.6%)560451 452241 240 262(+8.9%)598279(+6.1%)607298619319618339896 948 992 1 0201 128 1 222 1 289 1 3522016 2017 2018 2019 2020F 2021F 2022F 2023FCommercial drug segmentParapharmaceuticalsPublic procurementSource: DSM GroupAccording to the draft Strategy “Pharma-2030”, the forecasted volume of the market, takinginto account the financial and economic situation, may amount to RUB 5 trillion by 2030 inconsumer prices.The draft Strategy “Pharma-2030”, developed in 2018, contains a forecast of the dynamics ofmedicines export volumes under the “no change” and target scenarios until 2030. With theimplementation of the target scenario, the Russian export of medicines is expected to reachUSD 3,800 million by 2030.It is noted that the implementation of the target scenario depends on the correctunderstanding of macroeconomic trends and threats, creation of effective mechanisms toRUSSIAN-FINNISH LIFE SCIENCE INDUSTRYResearch and export directory35
Page 2 and 3: This publication was developed in t
Page 4 and 5: 1.5 Events ........................
Page 6 and 7: 2.42 PHARM-HOLDING ................
Page 8 and 9: 1 PART 1: MARKET RESEARCH1.1 Indust
Page 10 and 11: The Russian pharmaceutical market i
Page 12 and 13: Imported/localized drugs sales rati
Page 14 and 15: In 2020, the share of original drug
Page 16 and 17: 1.1.2 Commercial segment of the Rus
Page 18 and 19: 1.1.3 Drug reimbursement segmentAcc
Page 20 and 21: 1.1.4 Segment of purchases of drugs
Page 22 and 23: 1.1.5 Dietary supplements segmentAc
Page 24 and 25: The development of the innovative d
Page 26 and 27: Dynamics of pharmaceutical products
Page 28 and 29: § the term of the SPIC has been ex
Page 30 and 31: The Pharma-2030 Strategy elaboratio
Page 32 and 33: presence of viral RNA and antibodie
Page 36 and 37: counter external risks (for example
Page 38 and 39: 1.3.2 The Pavlov First Saint Peters
Page 40 and 41: 1.3.3 North-Western State Medical U
Page 42 and 43: 1.3.4 Military Medical Academy name
Page 44 and 45: 1.3.6 Saint-Petersburg State Instit
Page 46 and 47: 1.3.7 Peter the Great St. Petersbur
Page 48 and 49: 1.3.9 Saint-Petersburg Medico-Socia
Page 50 and 51: 1.4.2 Almazov National Medical Rese
Page 52 and 53: 1.4.4 Institute of Cytology RASInst
Page 54 and 55: 1.4.6 Kashkin Research Institute of
Page 56 and 57: 1.4.8 Research Institute of Hygiene
Page 58 and 59: 1.4.10 Saint-Petersburg Pasteur Ins
Page 60 and 61: Contact informationBekhtereva Str.,
Page 62 and 63: The Institute has Influenza and ARD
Page 64 and 65: 1.4.14 V. M. Gorbatov Federal Resea
Page 66 and 67: 1.5 Events1.5.1 Events calendarDate
Page 68 and 69: 1.5.2.2 Nordic Life Science DaysNor
Page 70 and 71: 1.5.2.4 HealthBIOThe HealthBIO even
Page 72 and 73: 1.5.2.6 BioJapanBioJapan has played
Page 74 and 75: 1.5.2.8 CPhI WorldwideCPhI is an es
Page 76 and 77: 1.5.2.10 INTERPHEX Japan 2021INTERP
Page 78 and 79: 1.5.3.2 IPhEB RussiaIPhEB Russia is
Page 80 and 81: 1.6 Clusters and associations1.6.1
Page 82 and 83: 1.6.3 Cluster of medical, environme
Page 84 and 85:
1.7 Cases and success stories1.7.1
Page 86 and 87:
1.8 Information sources1.8.1 Strate
Page 88 and 89:
§ DSM Group. Analytical report “
Page 90 and 91:
2.2 ALKOR BIOCompany profileThe St.
Page 92 and 93:
2.4 AMBERCompany profileAmber Group
Page 94 and 95:
2.6 AVENACompany profileAvena compa
Page 96 and 97:
2.8 BELKOZINCompany profileBelkozin
Page 98 and 99:
2.10 BIOCADCompany profileBiocad is
Page 100 and 101:
2.12 BIOPHARMOSCompany profileBioPh
Page 102 and 103:
2.14 BIOTECHCompany profileBiotech
Page 104 and 105:
2.16 CYTOMEDCompany profileCytomed
Page 106 and 107:
2.18 EKVUSCompany profile“Ekvus
Page 108 and 109:
2.20 FARMAKOGENCompany profileFarma
Page 110 and 111:
2.22 FRAMEBIOTEKCompany profileFram
Page 112 and 113:
2.24 GEROPHARMCompany profileGeroph
Page 114 and 115:
2.26 GROTEXCompany profileSolopharm
Page 116 and 117:
2.28 HARMSCompany profileHistory of
Page 118 and 119:
2.30 LEKKERCompany profileThe histo
Page 120 and 121:
2.32 NEPHRONCompany profileResearch
Page 122 and 123:
2.34 NIKACompany profileNika Factor
Page 124 and 125:
2.36 PHARM. ASSOCIATION NAMED FOR P
Page 126 and 127:
2.38 PHARMA VAMCompany profilePharm
Page 128 and 129:
2.40 PHARMAKOR PRODUCTIONCompany pr
Page 130 and 131:
2.42 PHARM-HOLDINGCompany profilePh
Page 132 and 133:
2.44 PHARMSYNTHEZCompany profilePha
Page 134 and 135:
2.46 PPDPCompany profileEnterprise
Page 136 and 137:
2.48 RESEARCH INSTITUTE OF INNOVATI
Page 138 and 139:
2.50 SEVERNAIA ZVEZDACompany profil
Page 140 and 141:
2.52 VITAL DEVELOPMENT CORPORATIONC
Page 142 and 143:
For notes142RUSSIAN-FINNISH LIFE SC
Page 144:
144RUSSIAN-FINNISH LIFE SCIENCE IND
show all

2021. RFLSP.Russian.Finnish.Life.Science.Industry.EN

Create successful ePaper yourself

Delete template?

Save as template?